ELV Earnings Prediction
The chart below shows how ELV performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ELV sees a -0.52% change in stock price 10 days leading up to the earnings, and a -1.04% change 10 days following the report. On the earnings day itself, the stock moves by -0.75%. This data can give you a slight idea of what to expect for the next quarter's release.
ELV Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
45.15B
5.36%
3.43%
Gross Margin
--
--
--
Operating Margin
4.39%
-28.85%
-36.65%
Net Margin
2.23%
-26.40%
-57.69%
EPS
4.36
-20.00%
-55.74%
No Data Available
ELV Earnings Analysis
Elevance Health, Inc. Corporation (ELV.N) Earnings Conference Call
Positive
Strong Earnings Performance: For the third quarter, adjusted diluted earnings per share were $8.37, reflecting strong operational performance despite elevated medical costs.
Quarterly Revenue Increase: Total operating revenue for the quarter was $44.7 billion, up over 5% year-over-year, indicating strong growth momentum.
Benefit Expense Ratio Improvement: The consolidated benefit expense ratio was 89.5% for the third quarter, an improvement of 270 basis points year-over-year, showcasing effective cost management strategies.
Member Retention Success: We ended the third quarter with 45.8 million members, flat sequentially, but reflecting strong customer retention efforts in a competitive market.
Healthcare Spending Management Expansion: Carelon Services is expanding its capabilities to manage a growing proportion of health care spending, supporting long-term growth in our business.
Negative
Earnings Per Share Miss: Adjusted diluted earnings per share were $8.37, which was below expectations due to elevated medical costs in our Medicaid business.
Membership Growth Stagnation: We ended the third quarter with 45.8 million members, flat sequentially, indicating a lack of growth in membership.
Medicaid Membership Loss Impact: The loss of approximately 85,000 Medicaid members due to a specific footprint change negatively impacted our revenue.
Benefit Expense Ratio Increase: The consolidated benefit expense ratio was 89.5% for the third quarter, an increase of 270 basis points year-over-year, primarily due to worsening Medicaid cost trends.
Earnings Outlook Reduction: We have reduced our fullyear outlook for adjusted diluted earnings per share to approximately $33, reflecting ongoing challenges in the Medicaid segment.
ELV FAQs
How does ELV typically perform around its earnings report dates?
Is Elevance Health, Inc. (ELV) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ELV Earning Call Sentiment
Elevance Health, Inc. (ELV) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ELV.N
-0.52%Positive
The earnings call summary and Q&A reveal several negative factors: elevated medical costs in Medicaid, inadequate rate increases, membership loss, and regulatory challenges. Despite revenue growth, the benefit expense ratio increased, and EPS missed expectations. The lack of a share repurchase program and challenges in Medicaid and Medicare Advantage further contribute to a negative outlook. While management is optimistic about future growth, the immediate concerns and uncertainties outweigh the positives, leading to a predicted stock price movement of -2% to -8% over the next two weeks.
